CAH · 10-Q · 2026Q3

CARDINAL HEALTH INC

Filed 2026-11-05 · Consumer · View original filing on EDGAR

Everything CAH's SEC filings said, ranked

Ranked Events

• Capital AllocationImportance 58 · Surprise 42
  During the three months ended September 30, 2026, Cardinal Health used $500 million for share repurchases, $157 million for capital expenditures, $149 million for acquisitions, and $126 million for dividends. The $500…
• Acquisitions and PartnershipsImportance 53 · Surprise 60
  On November 3, 2025, Cardinal Health completed its acquisition of Solaris Health, a urology managed services organization, through The Specialty Alliance for approximately $1.9 billion in cash, subject to adjustments.…
• Pharmaceutical Specialty DemandImportance 49 · Surprise 32
  Cardinal Health’s Pharma segment revenue increased 6% year over year to $62.6 billion, primarily from branded and specialty pharmaceutical sales growth with existing customers. The company also experienced increased…
• IRS Tax DisputesImportance 46 · Surprise 42
  In June 2026, the IRS issued a Notice of Proposed Adjustment in Cardinal Health’s fiscal 2015–2020 audit concerning its captive insurance company and net operating loss carrybacks under the CARES Act. The IRS is…
• Opioid Litigation LiabilityImportance 44 · Surprise 24
  As of September 30, 2026, Cardinal Health had accrued $3.9 billion for opioid-related matters. It had paid the Settling Governmental Entities approximately $2.6 billion and expects to pay them up to an additional $3.7…
• Liquidity and Cash PositionImportance 43 · Surprise 32
  At September 30, 2026, cash and equivalents were $5.264 billion, up from $4.856 billion at June 30, 2026, while total long-term obligations, including current obligations and short-term borrowings, were $8.8 billion,…
• Gross Margin DriversImportance 42 · Surprise 40
  Gross margin increased 12% year over year to $2.596 billion in the three months ended September 30, 2026. The increase was primarily driven by the acquisition of MSO platforms, contributions from branded and specialty…
• Segment ProfitabilityImportance 41 · Surprise 48
  Pharmaceutical and Specialty Solutions segment profit increased 17% year over year to $783 million, reflecting increased contributions from branded and specialty pharmaceutical products and the generics program. Global…
• Patient Recovery Tax DisputeImportance 40 · Surprise 42
  In February 2026, the IRS issued a Notice of Proposed Adjustment related to the restructuring connected with Cardinal Health’s July 2017 acquisition of the Patient Recovery business. The IRS asserts that the…
• Trade Policy and TariffsImportance 40 · Surprise 42
  An April 2026 U.S. presidential proclamation imposed tariffs on imported branded pharmaceuticals and associated ingredients; manufacturer price increases or stopped imports could raise costs or disrupt supply. From…
• Pharmaceutical Pricing PolicyImportance 40 · Surprise 42
  The Inflation Reduction Act has capped prices for certain drugs and is expected to continue adversely affecting Cardinal Health’s revenue, although profitability has not been materially impacted. The Executive Order…
• Geographic Revenue PerformanceImportance 36 · Surprise 14
  United States revenue was $67,113 million for the three months ended September 30, 2026, up 5.5% from $63,611 million in the comparable 2025 quarter. The filing reports total revenue of $67,513 million for 2026 and…
• Revenue Performance and MixImportance 36 · Surprise 14
  For the three months ended September 30, 2026, total revenue increased 5.5% to $67,513 million from $64,009 million a year earlier, a $3,504 million increase. Pharmaceutical and Specialty Solutions revenue rose 5.7% to…
• Tariff Costs and RefundsImportance 34 · Surprise 42
  Cardinal Health paid approximately $200 million in IEEPA tariffs between February 2025 and 2026, primarily on products sourced, manufactured, or distributed through Global Medical Products and Distribution. By…
• Iran Conflict Cost ImpactImportance 32 · Surprise 24
  The conflict in Iran has driven higher-than-anticipated fuel and transportation costs across Cardinal Health. It has also increased costs for products manufactured or distributed by GMPD. The company may not offset…
• Segment Asset GrowthImportance 30 · Surprise 14
  Total assets increased 3.9% to $59,544 million at September 30, 2026, from $57,299 million at June 30, 2026, a rise of $2,245 million. Pharmaceutical and Specialty Solutions assets increased $1,695 million to $42,472…
• Operating Earnings GrowthImportance 29 · Surprise 22
  GAAP operating earnings for the three months ended September 30, 2026 increased 13% year over year to $753 million, primarily from higher contributions from branded and specialty pharmaceutical products and the…
• Income Tax Rate ChangesImportance 28 · Surprise 30
  Cardinal Health’s effective tax rate was 19.2% for the three months ended September 30, 2026, compared with 24.1% in the prior-year quarter, a decrease of 4.9 percentage points. The filing attributes effective-rate…
• Regulatory RiskImportance 23 · Surprise 24
  In November 2023, Cardinal Health received a Department of Justice Civil Investigative Demand concerning potential Anti-Kickback Statute and False Claims Act violations. The inquiry relates to a 2022 transaction in…

Revenue by Product (in millions)

Revenue by Geography (in millions)